CASP12 Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q6UXS9 |
---|---|
Clone Names | 101008110 |
Gene ID | 100506742 |
---|---|
Other Names | Inactive caspase-12, CASP-12, CASP12 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CASP12 |
---|---|
Function | May function as a negative regulator of inflammatory responses and innate immunity. May reduce cytokine release in response to bacterial lipopolysaccharide during infection. Reduces activation of NF-kappa-B in response to TNF (PubMed:15129283). May lack protease activity (Probable). |
Tissue Location | Widely expressed, with highest levels in lung. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Caspases are cysteine proteases that cleave C-terminalaspartic acid residues on their substrate molecules. This gene ismost highly related to members of the ICE subfamily of caspasesthat process inflammatory cytokines. In rodents, the homolog ofthis gene mediates apoptosis in response to endoplasmic reticulumstress. However, in humans this gene contains a polymorphism forthe presence or absence of a premature stop codon. The majority ofhuman individuals have the premature stop codon and produce atruncated non-functional protein. The read-through codon occursprimarily in individuals of African descent and carriers haveendotoxin hypo-responsiveness and an increased susceptibility tosevere sepsis. Several alternatively spliced transcript variantshave been noted for this gene.
References
Lee, H.J., et al. Arch. Biochem. Biophys. 502(1):68-73(2010)Plantinga, T.S., et al. J. Acquir. Immune Defic. Syndr. 55(1):87-94(2010)McCall, M.B., et al. Eur. Cytokine Netw. 21(2):77-83(2010)Kachapati, K., et al. Hum. Mutat. 27 (9), 975 (2006) :Xue, Y., et al. Am. J. Hum. Genet. 78(4):659-670(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.